2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart …

JA Joglar, MK Chung, AL Armbruster, EJ Benjamin… - Circulation, 2024 - Am Heart Assoc
AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …

Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis

WL Chan, VCL Chong, IJY Wee, LM Poon… - Blood Cancer …, 2023 - nature.com
Rituximab-based chemo-immunotherapy is currently the standard first-line treatment for
Waldenstrom macroglobulinaemia (WM), while ibrutinib has emerged as an alternative. In …

Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management

MA Gertz - American journal of hematology, 2023 - Wiley Online Library
Abstract Disease Overview Waldenström macroglobulinemia (WM) is a lymphoplasmacytic
lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include …

Cardiac fibrosis in oncologic therapies

RRS Packard - Current opinion in physiology, 2022 - Elsevier
Cardiotoxicity, or the development of unwarranted cardiovascular side-effects of oncologic
therapies, can involve all aspects of cardiovascular disease. The development of cardiac …

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart …

WC Members, JA Joglar, MK Chung… - Journal of the American …, 2024 - Elsevier
Abstract Aim The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management
of Patients With Atrial Fibrillation” provides recommendations to guide clinicians in the …